← All trials
NCT04464980
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2020
- Primary completion
- Jul 31, 2025
- Completion date
- Jul 31, 2025
- First posted
- Jul 9, 2020
- Last posted
- Jul 9, 2020
- Enrollment
- 1630
- Arms / groups
- 16 / —
- Source
- AACT · ingestion pipeline
Sponsors
- New York UniversityLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Columbia UniversityCollaborator
- Mclean HospitalCollaborator
- Harvard UniversityCollaborator
- Columbia UniversityCollaborator
- Columbia UniversityCollaborator
- The EMMES CorporationCollaborator
- Columbia UniversityOverall official - principal investigator
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- New York UniversityOverall official - principal investigator
- The EMMES CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.